Filing summary
Entity and period: The supplied filing is BiondVax Pharmaceuticals Ltd.’s Form 10-K for the fiscal year ended December 31, 2022, filed April 17, 2023. It is not identified as a Scinai Immunotherapeutics Ltd. filing; investors should verify the company and filing identity. This is an annual report, not a stand-alone fourth-quarter report. Financial statement amounts below are in U.S. dollars; financial tables generally report in thousands.
Business context and developments
BiondVax is an early-stage biopharmaceutical company with no product revenue. After its M-001 universal influenza vaccine failed to meet Phase 3 efficacy endpoints, the company shifted its focus to nanosized antibodies (NanoAbs), licensed and developed with the Max Planck Society (MPG) and University Medical Center Göttingen (UMG). Its pipeline includes a COVID-19 program and discovery work aimed at targets relevant to psoriasis, psoriatic arthritis and asthma. The filing describes additional target programs, including wet macular degeneration.
The company reported positive preclinical hamster results for inhaled COVID-19 NanoAb, including reduced weight loss and lower lung viral titers versus placebo. These are animal-study findings, not evidence of clinical efficacy in people. The Paul Ehrlich Institute gave supportive scientific advice on a proposed Phase 1/2a study in sick patients; the company was evaluating whether and when to proceed. The filing reports no product candidate in human clinical development as of the reporting period.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $5.765 million | $3.249 million |
| General and administrative expense | $5.296 million | $7.625 million |
| Operating loss | $11.061 million | $10.862 million |
| Net loss | $5.796 million | $8.206 million |
| Net loss per ordinary share | $0.01 | $0.02 |
| Net cash used in operating activities | $7.265 million | $7.426 million |
Operating margins and revenue growth are not meaningful because the company reported no revenue. The smaller net loss in 2022 primarily reflects higher net financial income, including income associated with remeasurement of the EIB loan; operating loss nevertheless increased slightly. R&D expense rose by $2.516 million, attributed mainly to personnel, MPG-related and COVID-19 program costs. G&A expense fell by $2.329 million, including lower share-based compensation and professional and insurance expenses.
- Cash and liquidity: At December 31, 2022, cash and cash equivalents were $14.075 million, versus $17.374 million a year earlier; restricted cash was $0.140 million. Working capital was reported as $6.7 million. The audited balance sheet reports current assets of $14.370 million and current liabilities of $2.338 million.
- Cash flows: Audited cash flows show $7.265 million used in operations, $0.836 million used in investing, and $6.776 million provided by financing. Cash, cash equivalents and restricted cash decreased by $3.302 million. The MD&A separately describes investing cash use as $2.2 million and refers to short-term deposits; that description does not clearly reconcile with the audited cash flow statement and balance sheet.
- Debt and other liabilities: The EIB loan’s carrying amount was $20.082 million, while nominal principal was $25.596 million. The loan was restructured with maturity extended to December 2027; interest accrues at 7% from January 1, 2022, with payments deferred and added to principal. Ten percent of future capital raises is allocated to repayment. The EIB holds a first-ranking floating charge over substantially all company assets, subject to stated exclusions. The balance sheet also reports a $5.329 million warrant liability.
- Equity and financing: Shareholders’ equity was negative $1.760 million at year-end, versus positive $0.982 million in 2021; accumulated deficit was $115.835 million. A December 2022 offering raised $8 million gross and $7.231 million net, with warrants. Shares outstanding at year-end were 989.3 million, compared with 739.0 million at year-end 2021. The November 2022 ADS ratio change from 1 ADS per 40 ordinary shares to 1 per 400 had the effect of a 1-for-10 reverse split of ADSs.
Outlook, risks and unusual items
Management expects continuing operating losses and negative cash flow. It stated that available resources were expected to fund operations for at least 12 months, but this assessment depends on assumptions and includes a cost-saving plan that could reduce headcount and defer or cancel capital spending. The company said additional financing will be needed to advance development and that no new financing commitment had been secured. Future development plans are conditional on funding.
Key risks include clinical and regulatory failure, the early stage and novelty of the NanoAb platform, changing COVID-19 variants and demand, reliance on MPG/UMG and other partners, manufacturing and facility risks, dilution and access to capital, and the EIB’s secured-creditor rights and default provisions. The filing also identifies Nasdaq listing compliance risk: the company had received prior notices relating to stockholders’ equity and bid price, and warned of possible further equity-related noncompliance. It reports no material litigation pending.
Unusual accounting and reporting matters include substantial EIB-loan-related financial income and expense, a warrant liability recorded at fair value, and a change to U.S. GAAP and U.S. dollar reporting following loss of foreign-private-issuer status effective January 1, 2023; comparative statements were recast. The auditor issued an unqualified opinion and identified liquidity and capital resources as a critical audit matter. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not opine on internal control.
Most important facts for investors to verify
- Confirm the filing belongs to BiondVax, not Scinai Immunotherapeutics, and use the audited FY 2022 statements rather than treating this as Q4-only reporting.
- Reconcile the MD&A’s stated $2.2 million investing cash use and reference to short-term deposits with the audited $0.836 million investing cash outflow and balance-sheet cash presentation.
- Assess the cash runway against actual burn, the assumptions behind the 12-month estimate, and the potential implementation of cost cuts or need for new financing.
- Review the EIB loan’s carrying value versus nominal principal, revised repayment terms, collateral, management-consent requirements and potential default or acceleration triggers.
- Track clinical-stage progress, regulatory plans and whether preclinical COVID-19 results translate to human safety and efficacy; also assess variant relevance and the prioritization of other NanoAb programs.
- Evaluate dilution from the 2022 warrants and subsequent equity issuance, negative shareholders’ equity, and any updated Nasdaq listing notices.